Want to see NVNO full AI Analyst Report?
enVVeno Medical (NVNO) Stock Forecast & Price Target
NVNO Analyst Ratings
There are no analyst ratings in the last 3 months.
NVNO Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Jeffrey Cohen | Ladenburg Thalmann & Co. | $30 | buy | 328.57%Upside | Upgraded | 07/06/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Jeffrey CohenLadenburg Thalmann & Co. | BuyUpgraded$30 | 07/06/26 | 328.57%Upside |
Best Analysts Covering enVVeno Medical
Copying Anthropic Medical - Devices's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +23.25% per trade.
Copying Anthropic Medical - Devices's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.25% per trade.
Copying Anthropic Medical - Devices's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +23.25% per trade.
NVNO Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 0 | 1 | 1 | 1 | 0 |
In the current month, NVNO has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NVNO average Analyst price target in the past 3 months is ―.
NVNO Financial Forecast
NVNO Earnings Forecast
Next quarter’s earnings estimate for NVNO is -$6.29 with a range of ― to ―. The previous quarter’s EPS was -$6.29. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
NVNO Sales Forecast
Next quarter’s sales forecast for NVNO is $0 with a range of ― to ―. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
